Subtype
Renal Cell Carcinoma
CI-CAN-00006578RCCExplore in graph →
376 active trials17 approved drugs60 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006578RCCExplore in graph →
Clinical trials
1,622 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (276)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01062178 | Efficacy of Ultrasound Contrast Agent to Assess Renal Masses | completed | Phase 2 | 167 | University Health Network, TorontoOTHER | 1 | Mar 8, 2016 | clinicaltrials |
| NCT02307474 | A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 3, 2016 | clinicaltrials |
| NCT02370290 |
| Quantitative Imaging Metrics From CECT in Measuring Disease Response or Progression in Patients With Kidney Cancer |
| completed |
| — |
| 74 |
| University of Southern CaliforniaOTHER |
| 1 |
| Mar 3, 2016 |
| clinicaltrials |
| NCT02398552 | A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma. | unknown | Phase 2 | 80 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 1, 2016 | clinicaltrials |
| NCT00227760 | Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Feb 29, 2016 | clinicaltrials |
| NCT01014065 | A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect)(SUPER) | completed | — | 42 | AHS Cancer Control AlbertaOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT01924156 | DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT00334282 | Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma | completed | Phase 3 | 435 | GlaxoSmithKlineINDUSTRY | 25 | Feb 5, 2016 | clinicaltrials |
| NCT01402089 | Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients | completed | Phase 4 | 54 | Markus JoergerOTHER | 1 | Feb 2, 2016 | clinicaltrials |
| NCT01762033 | A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma | terminated | Phase 2 | 40 | Lpath, Inc.INDUSTRY | 1 | Jan 20, 2016 | clinicaltrials |
| NCT00324870 | Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer | completed | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jan 13, 2016 | clinicaltrials |
| NCT01390519 | A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor(OSAT) | completed | — | 30 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 13, 2016 | clinicaltrials |
| NCT00531544 | A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248 | completed | N/A | 350 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Jan 5, 2016 | clinicaltrials |
| NCT00618982 | Sorafenib Dose Escalation in Renal Cell Carcinoma | completed | Phase 2 | 83 | BayerINDUSTRY | 5 | Dec 24, 2015 | clinicaltrials |
| NCT01771003 | Remote Ischemia Pre-Conditioning in Patients Undergoing Partial Nephrectomy | terminated | N/A | 21 | University Health Network, TorontoOTHER | 1 | Dec 10, 2015 | clinicaltrials |
| NCT00480389 | Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal | completed | Phase 2 | 19 | University Health Network, TorontoOTHER | 1 | Dec 9, 2015 | clinicaltrials |
| NCT00480935 | A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma | terminated | Phase 2 | 3 | University Health Network, TorontoOTHER | 1 | Dec 9, 2015 | clinicaltrials |
| NCT01223027 | Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 3 | 564 | Novartis PharmaceuticalsINDUSTRY | 27 | Dec 7, 2015 | clinicaltrials |
| NCT00625456 | Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors | completed | Phase 1 | 23 | Jennerex BiotherapeuticsINDUSTRY | 2 | Dec 3, 2015 | clinicaltrials |
| NCT00694096 | Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response | completed | Phase 1 | 25 | University of UtahOTHER | 1 | Dec 1, 2015 | clinicaltrials |
| NCT00913913 | Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients | terminated | Phase 2 | 8 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Dec 1, 2015 | clinicaltrials |
| NCT01977586 | Functional Imaging in the Assessment of mRCC Response to Sunitinib | withdrawn | N/A | 0 | Imperial College Healthcare NHS TrustOTHER | 1 | Nov 23, 2015 | clinicaltrials |
| NCT01122615 | Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC) | completed | Phase 1 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 18, 2015 | clinicaltrials |
| NCT01227213 | The Vascular and Metabolic Effects of Sunitinib in Patients With Metastatic Renal Cell Carcinoma | completed | — | 20 | Radboud University Medical CenterOTHER | 1 | Oct 30, 2015 | clinicaltrials |
| NCT01525017 | A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer | completed | Phase 1 | 12 | MendusINDUSTRY | 1 | Oct 12, 2015 | clinicaltrials |
| NCT00842790 | Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging(REMISCAN) | completed | — | 107 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT01342627 | Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma(SERCC) | terminated | Phase 2 | 4 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT01548482 | Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2015 | clinicaltrials |
| NCT01012011 | Regulatory Post Marketing Surveillance Study on Nexavar® | completed | — | 2,845 | BayerINDUSTRY | 1 | Sep 21, 2015 | clinicaltrials |
| NCT01100242 | Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 17 | New Mexico Cancer Research AllianceOTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT02002312 | Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer | completed | Phase 2 | 14 | Radboud University Medical CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT00574483 | Treatment of Advanced Renal Cell Carcinoma With Quinacrine | withdrawn | Phase 2 | 0 | Cleveland BioLabsINDUSTRY | 1 | Aug 3, 2015 | clinicaltrials |
| NCT00609934 | Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone | completed | Phase 1 / Phase 2 | 12 | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00420888 | ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma | completed | Phase 2 / Phase 3 | 526 | Active Biotech ABINDUSTRY | 5 | Jul 22, 2015 | clinicaltrials |
| NCT01997788 | The Intrathecal Morphine for Nephrectomy(EMPON) | completed | N/A | 46 | Seoul National University HospitalOTHER | 1 | Jul 3, 2015 | clinicaltrials |
| NCT00126490 | Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2015 | clinicaltrials |
| NCT02001493 | Metabolomic Profiling in Renal Cell Carcinoma | unknown | — | 60 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Jun 23, 2015 | clinicaltrials |
| NCT00854620 | Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer | completed | Phase 2 | 9 | Stanford UniversityOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT00176280 | Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | University of KentuckyOTHER | 0 | Jun 18, 2015 | clinicaltrials |
| NCT00855452 | Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors(rIL-2(LAK)) | completed | Phase 2 | 20 | Hadassah Medical OrganizationOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT02030717 | Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma(ASA) | completed | Phase 2 / Phase 3 | 120 | Umeå UniversityOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00796757 | A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC). | completed | Phase 2 | 146 | Hoffmann-La RocheINDUSTRY | 12 | May 27, 2015 | clinicaltrials |
| NCT00083109 | Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer | completed | Phase 1 / Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | May 25, 2015 | clinicaltrials |
| NCT00743054 | microRNA Expression in Renal Cell Carcinoma | completed | — | 50 | Sun Yat-sen UniversityOTHER | 1 | May 21, 2015 | clinicaltrials |
| NCT00731211 | Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 57 | SCRI Development Innovations, LLCOTHER | 1 | May 20, 2015 | clinicaltrials |
| NCT02417194 | Prognostic Significance of Preoperative Hemoglobin A1c (HbA1c) in Renal Cell Carcinoma | unknown | — | 238 | Seoul National University HospitalOTHER | 1 | May 7, 2015 | clinicaltrials |
| NCT01827254 | Sutent Rechallenge In mRCC Patients(RESUME) | completed | — | 61 | PfizerINDUSTRY | 1 | Apr 30, 2015 | clinicaltrials |
| NCT01507740 | Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients | terminated | — | 60 | Medical University InnsbruckOTHER | 1 | Apr 29, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Mar 8, 2016source: clinicaltrials